In this issue:
Safety data differ between RA and psoriasis
Psoriasis marked by premature mortality
Brodalumab in generalised pustular psoriasis + psoriatic erythroderma
Increase skin cancer surveillance in biologics users?
Psoriasis linked to melanoma and haematological cancers
Guselkumab vs adalimumab in moderate-to-severe psoriasis
Ixekizumab maintenance shows acceptable safety in psoriasis
Few IBD cases with ixekizumab
Calcipotriol/betamethasone dipropionate gel: maintenance regimens compared
Apremilast improves PROs in moderate-to-severe psoriasis
Please login below to download this issue (PDF)